PTC - Ataluren (PTC124-041)
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Summary
This study is a randomized, double-blind, placebo-controlled, 72-week study, followed by a 72-week open-label period. The purpose is to characterize the long-term effects of ataluren-mediated dystrophin restoration on disease progression.
Study Number: NCT03179631
Description by PTC Therapeutics, Inc.
This study is a randomized, double-blind, placebo-controlled, 72-week study, followed by a 72-week open-label period. The purpose is to characterize the long-term effects of ataluren-mediated dystrophin restoration on disease progression. Participants will be randomized in a 1:1 ratio to ataluren or placebo. Participants will receive blinded study drug three times daily (TID) at morning, midday, and evening for 72 weeks, after which all participants will receive open-label ataluren for an additional 72 weeks (144 weeks in total). Study assessments will be performed at clinic visits every 12 weeks during the double-blind period and every 24 weeks during the open-label period. The total sample size of ~250 subjects will include ~160 subjects who meet the criteria for inclusion in the primary analysis population (age 7 to 16 years old, baseline six minute walk distance (6MWD) greater than or equal to (>=) 300 meters, supine to stand >= 5 seconds). The study will be conducted in the United States and other countries around the world.
Primary Outcome Measures
- Slope of Change in 6-Minute Walk Distance (6MWD) Over 72 Weeks [ Time Frame: 72 weeks ]
Secondary Outcome Measures
-
Change from Baseline to Week 72 in 6MWD [ Time Frame: Baseline, Week 72 ]
-
Change from Baseline to Week 72 in Time to Run/Walk 10 Meters [ Time Frame: Baseline, Week 72 ]
-
Change from Baseline to Week 72 in Time to Climb 4 Stairs [ Time Frame: Baseline, Week 72 ]
-
Change from Baseline to Week 72 in Time to Descend 4 Stairs [ Time Frame: Baseline, Week 72 ]
-
Change from Baseline to Week 72 in North Start Ambulatory Assessment (NSAA) Total Score [ Time Frame: Baseline, Week 72 ]
-
Time to Loss of Ambulation Over 72 Weeks [ Time Frame: 72 weeks ]
-
Time to Loss of Stair-Climbing Over 72 Weeks [ Time Frame: 72 Weeks ]
-
Time to Loss of Stair-Descending Over 72 Weeks [ Time Frame: 72 weeks ]
-
Risk of Loss of NSAA Items Over 72 weeks [ Time Frame: 72 weels ]
-
Number of Treatment-Emergent Adverse Events Considered Related to Study Drug [ Time Frame: 72 weeks ]
Can I take part?
Inclusion Criteria
-
Males aged 5 years and older (≥5 years)
-
Phenotypic evidence of Duchenne Muscular Dystrophy
-
Nonsense point mutation in the dystrophin gene
-
Use of systemic corticosteroids (prednisone/prednisolone or deflazacort)for a minimum of 12 months immediately prior to start of study treatment, with no significant change in dosage or dosing regimen for a minimum of 3 months immediately prior to start of study treatment
-
6-minute walking distance (6MWD) of greater than or equal to (≥) 150 meters
-
Ability to perform timed function tests within 30 seconds
-
Willingness and ability to comply with scheduled visits, drug administration plan, study procedures, laboratory tests, and study restrictions.
Exclusion Criteria
-
Any change in prophylaxis treatment for cardiomyopathy within 1 month prior to start of study treatment.
-
Ongoing intravenous (IV) aminoglycoside or IV vancomycin therapy.
-
Prior or ongoing therapy with ataluren.
-
Known hypersensitivity to any of the ingredients or excipients of the study drug
-
Exposure to another investigational drug within 6 months prior to start of study treatment, or ongoing participation in any interventional clinical trial.
-
History of major surgical procedure within 12 weeks prior to start of study treatment, or expectation of major surgical procedure during the 72-week placebo-controlled treatment period.
-
Requirement for daytime ventilator assistance or any use of invasive mechanical ventilation via tracheostomy.
-
Uncontrolled clinical symptoms and signs of congestive heart failure
-
Elevated serum creatinine or cystatin C at screening.
Other inclusion/exclusion criteria apply.
Download PDF
Trial complete
PTC Therapeutics, Inc.